Epilepsy– Emerging Therapies will break the market stagnancy

Epilepsy is a chronic problem with a repeated pattern of seizures. Nerve cells in the brain fire electrical impulses at a rate which is four times higher than the normal, causing an electrical storm in the brain leading to seizures. It can have many possible causes from anything that disturbs the normal pattern of neuron activity – from illness to brain damage to abnormal brain development etc. Epilepsy Seizures are of three main types: Focal onset seizures (partial seizures), generalized seizures and Unknown onset seizures (Types are as per ILAE).

According to the latest report of DelveInsight, “Epilepsy- Market Insights, Epidemiology and Market Forecast2025”, In 2016 total number of prevalent Epilepsy cases were estimated around 7 million in 7MM. Out of the total estimated cases, United States accounted for 4 million prevalent epilepsy cases. The United States dominates the global antiepileptic drugs market mainly due to extensive research and development activities in the neurology and presence of large pharmaceutical companies in this region. Among EU5, Germany has shown the highest prevalent population, followed by the United Kingdom with Spain having the least prevalent population of Epilepsy.

According to International League against Epilepsy (ILAE) (Epilepsy Foundation), Epilepsy is the fourth most common neurological disorder and it affects people of all ages. Further, Prevalence of Epilepsy is more in Males in comparison to Females.  Epilepsy therapeutic market is estimated to grow at a CAGR of 5.46% (2017-2025).

For years, the anti-epileptic market remained flooded with various anti-epileptic drugs having similar mechanism of action. More than 50% of the drugs have gone off-patent increasing generic products and causing stagnancy in the growth rate of anti-epileptic market. However, the dynamics have shifted to second and third generation anti-epileptics in the recent years. Upcoming Phase III stage products are expected to cover a significant market of Epilepsy. Three emerging drugs SAGE547, Epidiolex and Fintepla are going to be the part of top 10 products by 2025. DelveInsight estimates, SAGE547 which is currently in phase III is expected to bring a significant increase in Market size.

The emerging new therapies are expected to show remarkable growth in the upcoming years and have the potential break the stagnancy caused by the generic products. This report has covered in-depth details about all the upcoming modes of treatment with complete drug profiling and comparative analysis. Country-wise market analysis and complete market scenario of the 7MM is provided taking into consideration all the unmet needs to better understand the areas of development. This report is a complete package to better understand the epilepsy market drivers and barriers and plan the strategy accordingly.

Reasons to buy:

  • The report will help develop business strategies by building a thorough understanding of recent market trends that shape up and drive the Epilepsy market.
  • The report will provide an understanding of the future market competition in the epilepsy market.
  • Insightful reviews of key market drivers and barriers will help the buyer assess the Epilepsy market intelligently.
  • The report will help organize sales and marketing efforts by identifying the best opportunities for Epilepsy in the US, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan.
  • The report will help in identifying strong upcoming players in the market, and will also help clients devise strategies to create a competitive edge over these players.
  • Get a free Sample Page: https://www.delveinsight.com/report-store/epilepsy-market-insights-epidemiology-and-market-forecast

Companies covered:

  • UCB
  • Pfizer
  • Eisai
  • Janssen
  • Lamictal
  • Novartis
  • GW Pharmaceuticals
  • Zogenix
  • Marinus Pharmaceuticals
  • Sage Therapeutics
  • And many others…………………….

Table of Contents:

1. Report Summary
2. Epilepsy Disease Background
2.1. Introduction
2.2. Causes
2.3. Symptoms
2.4. Classification
2.5. Risk factors
2.6. Diagnosis
2.7. TSC Mutations in Epilepsy
2.8. Current Treatment & Medical Practices
3. Epidemiology and Patient Population
3.1. Key Points:
4. United States
4.1. Prevalence of Epilepsy in United States
4.2. Gender specific prevalence in United States
4.3. Sub-type specific prevalence in United States
4.4. Prevalence of TSC associated Epilepsy in the United States
5. Germany
5.1. Prevalence of Epilepsy in Germany
5.2. Gender specific prevalence in Germany
5.3. Sub-type specific prevalence in Germany
5.4. Prevalence of TSC associated Epilepsy in the Germany
6. France
6.1. Prevalence of Epilepsy in France
6.2. Gender specific prevalence in France
6.3. Sub-type specific prevalence in France
6.4. Prevalence of TSC associated Epilepsy in the France
7. Italy
7.1. Prevalence of Epilepsy in Italy
7.2. Gender specific prevalence in Italy
7.3. Sub-type specific prevalence in Italy
7.4. Prevalence of TSC associated Epilepsy in the Italy
8. Spain
8.1. Prevalence of Epilepsy in Spain
8.2. Gender specific prevalence in Spain
8.3. Sub-type specific prevalence in Spain
8.4. Prevalence of TSC associated Epilepsy in the Spain
9. United Kingdom
9.1. Prevalence of Epilepsy in United Kingdom
9.2. Gender specific prevalence in United Kingdom
9.3. Sub-type specific prevalence in United Kingdom
9.4. Prevalence of TSC associated Epilepsy in the UK
10. Japan
10.1. Prevalence of Epilepsy in Japan
10.2. Gender specific prevalence in Japan
10.3. Sub-type specific prevalence in Japan
11. Treatment Algorithm
11.1. NICE Guidelines
11.2. Treatment options in the management of Epilepsy in patients with TSC
11.3. Epilepsy treatment in TSC: Clinical Recommendations
12. Unmet Needs
13. Competitive Landscape-Marketed Drugs
13.1. Vimpat: UCB
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Vimpat Sales
13.2. Lyrica: Pfizer
13.2.1. Drug Description
13.2.2. Product Profile
13.2.3. Lyrica Sales
13.3. Banzel: Eisai
13.3.1. Drug Description
13.3.2. Product Profile
13.3.3. Banzel Sales
13.4. Briviact : UCB Pharma
13.4.1. Drug Description
13.4.2. Product Profile
13.4.3. Briviact Sales
13.5. Keppra: UCB
13.5.1. Drug Description
13.5.2. Product Profile
13.5.3. Keppra Sales
13.6. Keppra XR (levetiracetam XR): UCB
13.6.1. Drug Description
13.6.2. Product Profile
13.6.3. Keppra Sales
13.7. Topamax: Janssen
13.7.1. Drug Production
13.7.2. Product Profile
13.7.3. Topamax Sales
13.8. Lamictal: GlaxoSmithKline
13.8.1. Drug Description
13.8.2. Product Profile
13.8.3. Lamictal Sales
13.9. Neurontin: Pfizer
13.9.1. Drug Description
13.9.2. Product Profile
13.9.3. Neurontin Sales
13.10. Zonegran: Eisai
13.10.1. Drug Description
13.10.2. Product Profile
13.10.3. Zonegran Sales
13.11. Trileptal: Novartis
13.11.1. Drug Description
13.11.2. Product Profile
13.11.3. Trileptal Sales
13.12. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai
13.12.1. Drug Description
13.12.2. Product Profile
13.12.3. Zebinix (Aptiom) Sales
13.13. Fycompa: Eisai
13.13.1. Drug Description
13.13.2. Product Profile
13.13.3. Fycompa Sales
14. Emerging Therapies
14.1. Upcoming Drugs
15. Epidiolex: GW Pharmaceuticals
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities
16. Fintepla: Zogenix
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities
17. PF-06372865: Pfizer
17.1. Product Description
17.2. Research & Development
18. UCB0942: UCB
18.1. Product Description
18.2. Research & Development
19. Ganaxolone: Marinus Pharmaceuticals
19.1. Product Description
19.2. Research & Development
19.3. Product Development Activities
20. SAGE-547: Sage Therapeutics
20.1. Product Description
20.2. Research and Development
20.3. Product Development Activities
21. Triheptanoin: Ultragenyx Pharmaceutical
21.1. Product Description
21.2. Research and Development
21.3. Product Development Activities
22. CPP-115: Catalyst Pharmaceuticals
22.1. Product Description
22.2. Research and development
22.3. Product Development Activities
23. ZYN002: Zynerba Pharma
23.1. Product Description
23.2. Research and Development
23.3. Product Development Activities
24. Market Size of Epilepsy
25. Global Market Size
25.1. Key Findings
25.2. Market Size of Top-10 Products (2016)
25.3. Market Size of Top-10 Products (2025)
25.4. Upcoming Drug Launches-Uptake
26. United States
26.1. Market Outlook of Epilepsy in United States
26.1.1 Approved Products Analysis-Impact on the Market
26.1.2 Upcoming Therapies Analysis- Impact on the Market post-launch
27. EU5
27.1. Market outlook of Epilepsy in EU5
27.1.1 Approved Products Analysis-Impact on the Market
27.1.2 Upcoming Therapies Analysis- Impact on the Market post-launch
28. Japan
28.1. Market outlook of Epilepsy in Japan
28.1.1 Approved Products Analysis-Impact on the Market
28.1.2 Upcoming Therapies Analysis- Impact on the Market post-launch
29. Market Drivers
30. Market Barriers
31. Appendix
31.1. Report Methodology
32. Consulting Services
33. Disclaimer
34. About DelveInsight

About DelveInsight:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making the long lasting decision for their businesses.

For more information, please contact: 
Shruti Thakur 
T: +91 -011-45689769 
sthakur@delveinsight.com; info@delveinsight.com 
www.delveinsight.com